SCHEMBL1316161

SCHEMBL1316161

Cc1cc(C)c([Si](Cl)(c2ccccc2)c2c(C)cc(C)cc2C)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.38
CYP2A6 P11509 1/20 0.38
PSMB5 P28074 2/20 0.36
FFAR4 Q5NUL3 1/20 0.35
TSHR P16473 2/20 0.35
ACHE P22303 2/20 0.35
LMNA P02545 2/20 0.35
ALOX12 P18054 1/20 0.35
C5AR1 P21730 1/20 0.33
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
MAPT P10636 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
HPGD P15428 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
NQO2 P16083 1/20 0.31
RAB9A P51151 1/20 0.31
RAPGEF4 Q8WZA2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1314158 0.96 CYP1A2 (0.38) CYP1A2CYP2A6PSMB5FFAR4TSHR
SCHEMBL1314718 0.83 ACHE (0.39) CYP1A2CYP2A6TSHRACHELMNA
SCHEMBL1315478 0.82 CYP1A2 (0.36) CYP1A2CYP2A6PSMB5FFAR4TSHR
SCHEMBL12814677 0.81 CYP1A2 (0.33) CYP1A2CYP2A6TSHRACHELMNA
SCHEMBL1314789 0.79 RAPGEF4 (0.39) CYP1A2CYP2A6TSHRLMNAMEN1
SCHEMBL10318861 0.79 CYP1A2 (0.34) CYP1A2CYP2A6PSMB5FFAR4TSHR
SCHEMBL1314281 0.78 ACHE (0.39) CYP1A2CYP2A6TSHRACHELMNA
SCHEMBL1314519 0.78 MAPT (0.39) CYP1A2CYP2A6TSHRACHELMNA
SCHEMBL1314356 0.78 MAPT (0.39) CYP1A2CYP2A6TSHRACHELMNA
SCHEMBL10320478 0.76 KDM4E (0.34) MEN1KMT2AKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163950-B2 Processes for the production of tri-organo-monoalkoxysilanes and process for the production of tri-organo-monochlorosilanes SHIN-ETSU CHEMICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-20110275849-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES BANNOU TADASHI 2011-11-10 US disclosed
US-8008521-B2 Processes for the production of tri-organo-monoalkoxysilanes and process for the production of tri-organo-monochlorosilanes HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) 2011-08-30 US disclosed
US-20090082585-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES BANNOU TADASHI 2009-03-26 US disclosed
US-7459577-B2 Reacting a chlorosilane with grignard reagent SHIN-ETSU CHEMICAL CO., LTD. (JP) 2008-12-02 US disclosed
US-20050070730-A1 Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes SHIN-ETSU CHEMICAL CO., LTD. (JP) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275849-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES MLX, HAX1, RPS4X CYP1A2 198/4885CYP2A6 1437/4885PSMB5 3528/4885
US-20090082585-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES MLX, HAX1, RPS4X CYP1A2 198/4885CYP2A6 1437/4885PSMB5 3528/4885
US-20050070730-A1 Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes MLX, HAX1, GRIA3 CYP1A2 255/4885CYP2A6 1350/4885PSMB5 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.